Table 1.
Clinical trials targeting histone methylation modifiers in digestive cancers
| Compound | Epigenetic targets | NCT number | Phase | Enrolled tumor entities | Status |
|---|---|---|---|---|---|
| Tazemetostat (EPZ-6438) | EZH2 | NCT03028103 | 1 | B-cell lymphoma or advanced solid tumor | Active, not recruiting |
| Tazemetostat (EPZ-6438) | EZH2 | NCT01897571 | 1/2 | Advanced solid tumors, B-cell lymphomas or follicular lymphoma | Active, not recruiting |
| Tazemetostat (EPZ-6438) | EZH2 | NCT03213665 | 2 | Relapsed or refractory advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders | Recruiting |
| Tazemetostat (EPZ-6438) | EZH2 | NCT03155620 | 2 | Relapsed or refractory advanced solid tumors, non-Hodgkin lymphomas, or histiocytic disorders | Recruiting |
| Tazemetostat (EPZ-6438) | EZH2 | NCT02875548 | 2 | Diffuse large B-cell lymphoma, follicular lymphoma, rhabdoid tumors, synovial/epitheliod sarcoma, mesothelioma, advanced solid tumors | Recruiting |
| Tazemetostat (EPZ-6438) | EZH2 | NCT04241835 | 1 | Advanced malignant solid tumor | Recruiting |
| Tazemetostat (EPZ-6438) | EZH2 | NCT02601950 | 2 | INI1-negative tumors or relapsed/refractory synovial sarcoma | Recruiting |
| Tazemetostat (EPZ 6438) | EZH2 | NCT03010982 | 1 | B-cell lymphomas or advanced solid tumors | Completed |
| Tazemetostat (EPZ-6438) | EZH2 | NCT03217253 | 1 | Metastatic or unresectable solid tumors or B-cell lymphomas | Withdrawn |
| GSK2816126 | EZH2 | NCT02082977 | 1 | Relapsed/refractory diffuse large B cell lymphoma, transformed follicular lymphoma, other non-Hodgkin’s lymphomas, solid tumors and multiple myeloma | Terminated |
| CPI-1205 | EZH2 | NCT03525795 | 1/2 | Advanced solid tumors | Active, not recruiting |